What are the most common in vitro drug-drug interaction study gaps?
Certara drug interaction science experts share data and experimental design gaps commonly found in in…
Certara2025年6月9日
Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
Director, Clinical Pharmacology, ORIC Pharmaceuticals SVP, Head of Simcyp PBPK Modeling Services, Certara Director, PBPK…
Certara2025年4月21日
Measuring metabolites in index clinical DDI studies
2025年2月7日A key drug development safety consideration is whether the drug candidate will interact…
Certara2025年2月7日
Optimizing DDI Knowledge throughout Drug Development
Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…
Certara2025年1月6日
Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug–Drug Interactions via Cytochromes P450: One Step Forward and Two Steps Backwards
Predicting metabolic drug–drug interactions (DDIs) via cytochrome P450 enzymes (CYP) is essential in drug development,…
Certara2024年12月12日
Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator
The article "Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system…
Certara2024年8月26日
ICH M12 Guidelines & Your Drug-Drug Interaction Package
We have provided an overview of the key changes to the ICH M12 drug-drug interaction…
Certara2024年6月19日
